scholarly journals Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) with Human Placenta-Derived Stem Cells (HPDSC) Combined with Unrelated Cord Blood (UCB) for Malignant and Non-Malignant Disorders (IND 14949)

2020 ◽  
Vol 26 (3) ◽  
pp. S280
Author(s):  
Allyson Flower ◽  
Lauren Harrison ◽  
Michael A. Pulsipher ◽  
Qiuhu Shi ◽  
Roger H. Giller ◽  
...  
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cord Blood ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Human Placenta ◽  
Hematopoietic Stem ◽  
Unrelated Cord Blood

scholarly journals Hematopoietic stem cell transplantation for patients with AML in first complete remission

Blood ◽  
2016 ◽  
Vol 127 (1) ◽  
pp. 62-70 ◽  
Author(s):  
Jan J. Cornelissen ◽  
Didier Blaise
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Residual Disease ◽  
Hematopoietic Stem ◽  
Recent Developments ◽  
Postremission Therapy

Abstract Postremission therapy in patients with acute myeloid leukemia (AML) may consist of continuing chemotherapy or transplantation using either autologous or allogeneic stem cells. Patients with favorable subtypes of AML generally receive chemotherapeutic consolidation, although recent studies have also suggested favorable outcome after hematopoietic stem cell transplantation (HSCT). Although allogeneic HSCT (alloHSCT) is considered the preferred type of postremission therapy in poor- and very-poor-risk AML, the place of alloHSCT in intermediate-risk AML is being debated, and autologous HSCT is considered a valuable alternative that may be preferred in patients without minimal residual disease after induction chemotherapy. Here, we review postremission transplantation strategies using either autologous or allogeneic stem cells. Recent developments in the field of alternative donors, including cord blood and haploidentical donors, are highlighted, and we discuss reduced-intensity alloHSCT in older AML recipients who represent the predominant category of patients with AML who have a high risk of relapse in first remission.

Sign in / Sign up

Export Citation Format

Share Document